Ginkgo Bioworks has been bolstering its position as a first mover in Synthetic Biology!

 . Here are the companies they’ve acquired and the reasons behind each acquisition:

1. Proof Diagnostics:

   -  Ginkgo Bioworks acquired Proof Diagnostics, a Cambridge-based CRISPR test developer co-founded by Feng Zhang (an early discoverer of Crispr technology) of the Broad Institute of MIT and Harvard. 
2. Proof Diagnostics has been working on a “future-proof” COVID-19 screener with a rapid tabletop analyzer capable of detecting not only COVID-19 but also the flu, respiratory syncytial virus, and other diseases using gene-editing technology. 
3. Ginkgo was mainly attracted to Proof Diagnostics for its intellectual property and libraries of RNA-programmable, non-Cas enzymes called OMEGAs. These emerging OMEGAs offer potential upgrades over current genomic medicine tools, making them easier to deliver into cells. Ginkgo plans to use these enzymes to support its gene therapy services, providing an alternative approach to gene editing.

4. Patch Biosciences: - Ginkgo acquired Patch Biosciences, a New York-based AI platform developer focused on computer-designed cargos for genetic medicines. By integrating Patch’s capabilities, libraries, and datasets, Ginkgo aims to enhance its existing genetic medicine toolkit. 

   The machine-learning models and downstream assays from Patch Biosciences will contribute to Ginkgo’s offerings.

5. Reverie Labs:

    - Ginkgo also acquired Reverie Labs, an AI-powered drug discovery company. Reverie Labs specializes in developing biology-focused foundation models and small molecule design. Four members of Reverie’s AI team, including Chief Technology Officer Ankit Gupta, have joined Ginkgo. 

   This acquisition will accelerate Ginkgo’s work in drug discovery and strengthen its expertise in biological engineering approaches.

Additionally, it’s worth noting that Ginkgo Bioworks made its largest acquisition to date by acquiring it's competitor, Zymergen, which is expected to significantly enhance Ginkgo’s platform by integrating strong automation and software capabilities. 

These acquisitions demonstrate Ginkgo’s commitment to advancing synthetic biology and expanding its capabilities in molecular medicine and AI-driven research. 

 Ginkgo Bioworks is an American biotech company founded in 2008 by five scientists from MIT, led by Jason Kelly. 

Their specialty lies in using genetic engineering to produce bacteria with industrial applications for other biotech companies. 

Essentially, they create custom-designed microorganisms that can be used in various fields, from agriculture to pharmaceuticals.

By doing so, they help other companies skip the costly initial stages of designing synthetic biology products. 

Their cell programming platform enables the growth of biotechnology across diverse markets, including food, fragrance, and pharmaceuticals

Ginkgo Bioworks Holdings (NYSE: DNA) is owned by 57.35% institutional shareholders, 13.56% by insiders, and 29.08% retail investors.

Article:

3 Reasons Why Cathie Wood Is Buying Ginkgo Bioworks Stock Hand Over Fist | The Motley Fool

KEY POINTS from this article:

• 
  
• 1.   The biofoundry's platform is scaling up, "big time" and customers are flocking.
• 2.
•        

  Powerful collaborators are signing up

  It's working with Merck, Moderna, Eli Lilly, and many others in biopharma and agriculture.

• 3  Ginkgo's valuation is attractive, and trading as a penny stock at all time lows!

Disclosure: we own stock in Ginkgo Bioworks ($DNA) and are accumulating!

Analysts high on Ginkgo and it's platform.

StockScan estimates an average price of $6.06 for Ginkgo Bioworks in 2025, with predictions ranging from a low of $4.78 to a high of $7.34​ (Stock Screener, Chart, and Price) This indicates a potential rise of approximately 980.45% from the last recorded price. While Ginkgo faces challenges, its long-term opportunities in #CellProgramming and #Biosecurity could drive significant growth. Keep in mind that investing involves risks, and it’s essential to conduct thorough research before making any investment decisions

I asked ChatGPT, What a merger between Twist Biosciences and Ginkgo Bioworks might do for the growth of Synthetic Biology!

"The rapid and complete resolution of aggressive MSS colorectal cancer tumors observed in this study is unprecedented in the field" says the author Dr. Kasi